Incyte Corporation $INCY Shares Sold by Todd Asset Management LLC

Todd Asset Management LLC cut its holdings in Incyte Corporation (NASDAQ:INCY) by 16.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 345,023 shares of the biopharmaceutical company’s stock after selling 69,454 shares during the period. Todd Asset Management LLC owned 0.18% of Incyte worth $29,261,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in Incyte by 0.7% in the second quarter. Vanguard Group Inc. now owns 20,135,393 shares of the biopharmaceutical company’s stock valued at $1,371,220,000 after purchasing an additional 137,570 shares during the last quarter. AQR Capital Management LLC boosted its stake in Incyte by 21.8% in the 2nd quarter. AQR Capital Management LLC now owns 8,201,455 shares of the biopharmaceutical company’s stock worth $558,519,000 after buying an additional 1,465,286 shares during the last quarter. Geode Capital Management LLC grew its holdings in Incyte by 3.3% in the 2nd quarter. Geode Capital Management LLC now owns 4,347,731 shares of the biopharmaceutical company’s stock valued at $294,899,000 after buying an additional 139,740 shares during the period. LSV Asset Management increased its stake in shares of Incyte by 3.2% during the 3rd quarter. LSV Asset Management now owns 3,986,097 shares of the biopharmaceutical company’s stock valued at $338,061,000 after acquiring an additional 124,266 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Incyte by 7.3% during the 2nd quarter. Invesco Ltd. now owns 3,401,018 shares of the biopharmaceutical company’s stock worth $231,609,000 after acquiring an additional 232,268 shares during the period. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Wall Street Analyst Weigh In

INCY has been the subject of a number of recent analyst reports. Zacks Research downgraded shares of Incyte from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Wells Fargo & Company dropped their price objective on Incyte from $107.00 to $101.00 and set an “equal weight” rating for the company in a report on Wednesday, February 11th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $90.00 target price on shares of Incyte in a research report on Thursday, January 8th. Piper Sandler boosted their price target on Incyte from $102.00 to $110.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Finally, HC Wainwright restated a “buy” rating and issued a $135.00 price objective on shares of Incyte in a report on Wednesday, February 11th. Nine investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $103.94.

Incyte Trading Up 0.3%

NASDAQ:INCY opened at $101.10 on Monday. Incyte Corporation has a 12 month low of $53.56 and a 12 month high of $112.29. The business’s 50-day moving average is $101.73 and its two-hundred day moving average is $94.31. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 3.25. The firm has a market capitalization of $20.12 billion, a PE ratio of 15.77, a price-to-earnings-growth ratio of 0.80 and a beta of 0.82.

Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). The company had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.35 billion. Incyte had a net margin of 25.03% and a return on equity of 26.34%. Incyte’s quarterly revenue was up 27.8% compared to the same quarter last year. During the same quarter last year, the business posted $1.43 EPS. Research analysts predict that Incyte Corporation will post 4.86 earnings per share for the current fiscal year.

Incyte News Roundup

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q4 results & guidance: Incyte reported Q4 revenue above expectations and outlined 10–13% revenue growth for 2026, citing pipeline expansion and new product launches — a clear near-term growth signal that investors rewarded. Incyte outlines 10–13% revenue growth for 2026
• Positive Sentiment: Analyst tone: Coverage pieces and aggregate analyst commentary remain constructive—Wall Street highlights steady growth and the pipeline, helping underpin sentiment despite the EPS miss. Do Wall Street Analysts Like Incyte Corporation Stock?
• Positive Sentiment: Asset monetization: Incyte sold the Wilmington Bracebridge towers to BPG, a real-estate disposition that should free cash / simplify the corporate footprint — modestly positive for cash flow and capital allocation. Incyte’s big downtown Wilmington move…
• Neutral Sentiment: Market commentary: Several pieces ask whether INCY’s ~43% one‑year run makes it “too late” to buy; these are opinion/valuation discussions that influence positioning but don’t change fundamentals immediately. Is It Too Late To Consider Incyte After Its 43% One Year Rally
• Neutral Sentiment: Media flow: Earnings-call highlights and coverage (transcripts, midday movers) are being digested; they offer color but largely reiterate the same beats/risks. Incyte Q4 Earnings Call Highlights
• Neutral Sentiment: Short-interest data appears inconsistent/erroneous in recent filings (reports show zero shares / NaN changes), so short-interest signals aren’t informative right now.
• Negative Sentiment: Opzelura guidance & Jakafi patent fears: A weaker 2026 revenue forecast for Opzelura raised renewed concerns about franchise vulnerability and potential spillover to Jakafi patent litigation/renewed competitive risk. Opzelura weak 2026 forecast heightens Jakafi patent concerns
• Negative Sentiment: EPS miss & share reaction: INCY missed on EPS for the quarter, which prompted a post‑earnings gap down in some sessions and is a key reason for caution despite the revenue beat. Shares Gap Down After Earnings Miss
• Negative Sentiment: Regulatory/pricing risk: Management flagged exposure to evolving U.S. drug‑pricing policies (e.g., Most Favored Nation‑style measures), which could pressure profitability if enacted. Profit Outlook Threatened by Pricing Policies

Insider Activity

In other news, EVP Michael James Morrissey sold 54,008 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $97.29, for a total transaction of $5,254,438.32. Following the completion of the sale, the executive vice president directly owned 31,830 shares in the company, valued at $3,096,740.70. This trade represents a 62.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Mohamed Khairie Issa sold 10,856 shares of Incyte stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $109.07, for a total value of $1,184,063.92. Following the sale, the executive vice president directly owned 66,132 shares in the company, valued at approximately $7,213,017.24. The trade was a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 95,225 shares of company stock valued at $9,519,745. 17.80% of the stock is currently owned by company insiders.

Incyte Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.